Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?

IF 5.6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Communications Pub Date : 2024-07-18 eCollection Date: 2024-08-01 DOI:10.1097/HC9.0000000000000470

Meng Zhu, Zhangcheng Wang, Xiangfeng Tian, Yongsheng Zhang

引用次数: 0

查看原文本刊更多论文

致编辑的信：利福霉素SV MMX优于安慰剂，但比较是否恰当？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Communications GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

8.00

自引率

2.00%

发文量

248

审稿时长

8 weeks

期刊介绍： Hepatology Communications is a peer-reviewed, online-only, open access journal for fast dissemination of high quality basic, translational, and clinical research in hepatology. Hepatology Communications maintains high standard and rigorous peer review. Because of its open access nature, authors retain the copyright to their works, all articles are immediately available and free to read and share, and it is fully compliant with funder and institutional mandates. The journal is committed to fast publication and author satisfaction.